Skip to main content
AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
226.08
-2.63 (-1.15%)
At close: Dec 5, 2025, 4:00 PM EST
226.45
+0.37 (0.16%)
After-hours: Dec 5, 2025, 7:55 PM EST

AbbVie Revenue by Segment
Period Ending Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019
Immunology
29.07B 28.24B 27.58B 26.68B 26.34B 26.08B 25.92B 26.14B
Immunology Growth
10.38% 8.27% 6.39% 2.09% -2.83% -6.78% -8.64% -9.64%
Neuroscience
10.32B 9.84B 9.32B 9.00B 8.58B 8.26B 7.99B 7.72B - - - - - - -
Neuroscience Growth
20.17% 19.03% 16.64% 16.61% 17.06% 18.70% 18.59% 18.21% - - - - - - -
Hematologic Oncology
6.68B 6.69B 6.65B 6.56B 6.37B 6.20B 6.04B 5.92B
Hematologic Oncology Growth
4.85% 7.89% 9.98% 10.82% 5.57% 0.37% -4.81% -10.07%
Aesthetics
4.87B 4.92B 5.03B 5.18B 5.25B 5.25B 5.24B 5.29B - - - - - - -
Aesthetics Growth
-7.18% -6.31% -4.08% -2.23% 0.75% -0.44% -0.30% -0.73% - - - - - - -
Other Products
3.76B 3.63B 3.56B 3.65B 3.70B 3.79B 3.78B 3.81B
Other Products Growth
1.62% -4.24% -5.85% -4.15% -3.14% -1.51% -2.50% -1.25%
HCV
- - - - - - - - - - - - - - - - - - - - - - 2.68B 2.93B 3.16B 3.32B
Eye Care
2.18B 2.19B 2.21B 2.24B 2.18B 2.26B 2.35B 2.42B - - - - - - -
Eye Care Growth
-0.28% -3.10% -5.76% -7.16% -9.88% -7.26% -7.60% -10.59% - - - - - - -
Women's Health
- - - - - - - - - - - - - - - 796.00M 829.00M 866.00M 822.00M - - - - - - -

Revenue by Geography
Period Ending Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019
United States
45.54B 44.62B 43.97B 43.03B 42.41B 42.11B 41.72B 41.88B
United States Growth
7.40% 5.97% 5.38% 2.74% -1.30% -4.03% -6.38% -8.38%
International
14.10B 13.71B 13.40B 13.31B 13.13B 12.89B 12.68B 12.44B
International Growth
7.41% 6.31% 5.68% 7.00% 7.85% 6.12% 4.15% 0.76%

Operating Expense Breakdown
Period Ending Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018
Selling, General, and Administrative
13.97B 14.61B 14.73B 14.75B 14.09B 13.26B 13.15B 12.87B
Selling, General, and Administrative Growth
-0.85% 10.18% 12.03% 14.61% 7.59% 1.76% -13.34% -15.65%
Research and Development
13.29B 13.10B 12.92B 12.79B 7.94B 7.54B 7.32B 7.68B
Research and Development Growth
67.31% 73.84% 76.44% 66.66% 5.39% 1.45% 0.23% 17.90%
Acquired In-Process R&D
5.33B 2.73B 2.84B 2.76B 1.47B 1.45B 792.00M 778.00M - - -
Acquired In-Process R&D Growth
263.48% 88.20% 258.71% 254.37% 98.24% 103.23% 12.82% 11.62% - - -
Other Expenses
- -62.00M - -352.00M - - - - - -358.00M -22.00M - - - - - - - - - - -
Other Expenses Growth
- - - - - - - - - - - - - - - - - - - - - -
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.